Clinical Trials
22 trialsNCT00322218 2022-01-19
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
NCT01510184 2021-12-16
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01549886 2021-10-04
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT01662102 2021-10-04
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00582166 2019-12-13
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
University of Wisconsin, Madison
Phase 2 Terminated
NCT00372905 2019-09-04
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Northwestern University
Phase 1/2 Terminated
NCT00089284 2019-08-14
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Northwestern University
Phase 1/2 Terminated
NCT00012298 2018-08-09
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00110149 2017-11-21
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Terminated
NCT01207765 2017-03-20
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Tufts Medical Center
Phase 2 Terminated
NCT01497275 2015-07-15
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Duke University
Phase 2 Terminated
NCT00033423 2013-12-13
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Alabama at Birmingham
Phase 1 Terminated
NCT00493454 2013-05-31
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00036855 2013-01-17
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00060294 2013-01-08
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT00902525 2012-12-31
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase 2 Terminated
NCT00386321 2010-11-18
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma
Chulalongkorn University
Phase 2 Terminated
NCT00354822 2009-09-18
Z0105
A.O. Ospedale Papa Giovanni XXIII
Phase 2 Terminated
NCT00057343 2006-09-12
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
Biogen
Phase 3 Terminated